Visceral Leishmaniasis in Pediatrics: A Case Series and a Narrative Review with Global Insights
- PMID: 40423365
- PMCID: PMC12115772
- DOI: 10.3390/tropicalmed10050136
Visceral Leishmaniasis in Pediatrics: A Case Series and a Narrative Review with Global Insights
Abstract
Visceral leishmaniasis (VL) is a severe parasitic disease caused by Leishmania spp., with a significant impact on pediatric populations, particularly in endemic regions. The diagnosis of VL in children requires a high index of suspicion, as clinical manifestations-such as prolonged fever, hepatosplenomegaly, and pancytopenia-overlap with other infectious and hematologic diseases. While serological and molecular tests aid in detection, bone marrow aspiration remains the gold standard for definitive diagnosis. In this case series, we describe five pediatric patients diagnosed with VL in Italy, emphasizing the importance of a timely and accurate diagnostic approach. Liposomal amphotericin B (LAmB) is the first-line treatment in Southern Europe due to its high efficacy and reduced toxicity. Our patients received a standard regimen of 3 mg/kg daily for five days, plus an additional dose on day 10, leading to rapid clinical improvement. However, some cases required supportive care, such as red blood cell transfusions, particularly in patients with co-infections. Despite being a neglected disease, VL is re-emerging in Europe, influenced by climate change, increased pet ownership, and migration from endemic regions. Prevention strategies focus on vector control, canine vaccination, and public health awareness. The global rise in pediatric VL highlights the need for improved surveillance, access to affordable treatments, and the development of effective vaccines to mitigate the disease burden in both endemic and non-endemic areas.
Keywords: bone marrow aspiration; hemophagocytic lymphohistiocytosis; liposomal amphotericin B; neglected tropical diseases; pediatric emergency department; vector control; visceral leishmaniasis; zoonosis.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Martín-Sánchez J., Rodríguez-Granger J., Morillas-Márquez F., Merino-Espinosa G., Sampedro A., Aliaga L., Corpas-López V., Tercedor-Sánchez J., Aneiros-Fernández J., Acedo-Sánchez C., et al. Leishmaniasis due to Leishmania infantum: Integration of human, animal and environmental data through a One Health approach. Transbound. Emerg. Dis. 2020;67:2423–2434. doi: 10.1111/tbed.13580. - DOI - PubMed
-
- Global Leishmaniasis Surveillance Updates 2023: 3 Years of the NTD Road Map. [(accessed on 1 April 2025)]. Available online: https://iris.who.int/bitstream/handle/10665/379491/WER9945-653-669.pdf.
-
- Silgado A., Armas M., Sánchez-Montalvá A., Goterris L., Ubals M., Temprana-Salvador J., Aparicio G., Chicharro C., Serre-Delcor N., Ferrer B., et al. Changes in the microbiological diagnosis and epidemiology of cutaneous leishmaniasis in real-time PCR era: A six-year experience in a referral center in Barcelona. PLoS Negl. Trop. Dis. 2021;15:e0009884. doi: 10.1371/journal.pntd.0009884. - DOI - PMC - PubMed
-
- Ehehalt U., Schunk M., Jensenius M., van Genderen P.J., Gkrania-Klotsas E., Chappuis F., Schlagenhauf P., Castelli F., Lopez-Velez R., Parola P., et al. Leishmaniasis acquired by travellers to endemic regions in Europe: A EuroTravNet multi-centre study. Travel. Med. Infect. Dis. 2014;12:167–172. doi: 10.1016/j.tmaid.2013.12.003. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
